The hypocretin/orexin receptor: therapeutic prospective in sleep disorders (Q36985867)

17 August 2017

1 reference

title

The hypocretin/orexin receptor: therapeutic prospective in sleep disorders (English)

1 reference

17 August 2017

Seiji Nishino

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1785-1797

1 reference

The hypocretin/orexin system in health and disease

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Promotion of sleep by targeting the orexin system in rats, dogs and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Effects of orexin on cultured porcine adrenal medullary and cortex cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Expression and coupling characteristics of the CRH and orexin type 2 receptors in human fetal adrenals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Hypocretin (orexin) deficiency in human narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Hypocretin levels in sporadic and familial cases of canine narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Behavioral correlates of activity in identified hypocretin/orexin neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Orexin A activates locus coeruleus cell firing and increases arousal in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Pharmacological aspects of human and canine narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Monoaminergic mechanisms and experimental cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Hypothalamic orexin neurons regulate arousal according to energy balance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Orexins activate histaminergic neurons via the orexin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Distribution of orexin neurons in the adult rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

SB-334867-A: the first selective orexin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

A selective orexin-1 receptor antagonist reduces food consumption in male and female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Orexinergic neurons and barbiturate anesthesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle-aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Epidemiology of insomnia: what we know and what we still need to learn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Insomnia and global sleep dissatisfaction in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Insomnia and its treatment. Prevalence and correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Anticonvulsant activity of a nonpeptide galanin receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Roles of orexins in regulation of feeding and wakefulness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Differential expression of orexin receptors 1 and 2 in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

Drugs for sleep disorders: mechanisms and therapeutic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.11.1785

10.1517/13543784.16.11.1785

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference